

REMARKS

Specification

The specification is amended to incorporate by reference, the CD copies of the sequence listing submitted under 37 C.F.R. §§ 1.821(c) and 1.52(e). No new matter is added by this amendment.

Sequence Listing

The sequence listing, submitted in duplicate on CD, in lieu of a paper copy, and on CD (CRF copy) in compliance with 37 C.F.R. §§ 1.821(c),(e) corresponds with the amendments made to Figures 18 and 19. The Sequence Listing has been generated from the specification and Figures and does not constitute new matter. The Sequence Listing has been prepared using PatentIn 3.3 and checked with Checker 4.2. No error has been found.


Figures

Replacement Figures 18 and 19 are amended to include the appropriate unique and non-redundant SEQ ID NOs., in compliance with 37 CFR §1.821-1.825. The amendments are indicated in red pen on the "annotated marked up drawing" sheets, attached herewith. These amendments do not constitute new matter.

Oath/Declaration

Applicants submit the Oath/Declaration for the application, executed by each inventor (37 C.F.R. §1.63). A check for the surcharge fee (\$65.00) associated with late filing of the oath/declaration is included.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

By: 
Christopher P. Singer
Reg. No. 48,701

Date: SEPT. 15, 2004

Sequence Listing:

Please incorporate the sequence listing into the application. The sequence listing is submitted herewith on CD in duplicate, in lieu of the paper copy, in compliance with 37 CFR §§ 1.821(c) and 1.52 and on CD in compliance with 37 CFR § 1.821(e) (CRF copy). The sequence listing does not contain new matter.


As required by 37 CFR § 1.821(f): the copy of the sequence listing on CD (in lieu of paper copy) is the same as the CRF copy of the sequence listing.



ANNOTATED MARKED UP

DRAWINGS

Figure 18



POSITIONS (NN) CAN COMprise ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES
(eg. THYMIDINE) OR UNIVERSAL BASES


B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP THAT IS OPTIONALLY PRESENT

L = GLYCERYL or B THAT IS OPTIONALLY PRESENT

S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE that is optionally absent

ANNOTATED MARKED UP
DRAWINGS

Figure 19



lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro

italic lower case = 2'-deoxy-2'-fluoro

underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY

iB = INVERTED DEOXYABASIC

L = GLYCERYL MOIETY or iB OPTIONAL PRESENT

S = PHOSPHOROTHIOATE OR
PHOSPHORODITHIOATE OPTIONAL PRESENT